Maximum quantity allowed is 999
请选择数量
CAS RN: 53-19-0 | 产品编码: M3304
Mitotane
×
![]()
×
| 产品编码 | M3304 |
| 纯度/分析方法 | >98.0%(GC) |
| 分子式/分子量 | C__1__4H__1__0Cl__4 = 320.03 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 室温 (15°C以下阴凉干燥处) |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 53-19-0 |
| Reaxys-RN | 2056007 |
| PubChem物质ID | 468592398 |
| Merck Index (14) | 6216 |
| MDL编号 | MFCD00000850 |
技术规格
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
| Melting point | 76.0 to 80.0 °C |
| Solubility in Methanol | almost transparency |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 78 °C |
| 水溶性 | 不溶 |
| 在水中的溶解度 | 0.1 mg/l 25 °C |
| 溶解性（可溶于） | 乙醇, 甲醇 |
GHS
| 象形图 |
|
| 信号词 | Danger |
| 危险性说明 | H370 : Causes damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H351 : Suspected of causing cancer. H413 : May cause long lasting harmful effects to aquatic life. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P405 : Store locked up. |
相关法规
| RTECS# | KH7880000 |
运输信息
| HS编码* | 2903.99-000 |
应用
Mitotane: An Adrenal-Specific Cytotoxic Agent with Steroid Synthesis Inhibition
Mitotane (o,p'-DDD) is an adrenal-specific cytotoxic agent with an unknown biochemical mechanism of action.1) Scientific reports suggest that mitotane modifies the peripheral metabolism of steroids as well as directly suppressing the adrenal cortex.2-4) Therefore, mitotane is used for the treatment of adrenocortical carcinoma (ACC) and Cushing's disease. Recently, mitotane (as an adjuvant) plus etoposide [E0675], doxorubicin [D4193] (HCl salt), and cisplatin [D3371] (called EDP-M) is the established first-line therapy for ACC.5) (The product is for research purpose only.)
References
- 1) Ultrastructure of Adrenal Cortex of the Dog during Treatment with DDD
- 2) Studies on the site of action of o,p’-DDD in the dog adrenal cortex. 1. Inhibition of ACTH-mediated pregnenolone synthesis
- 3) Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p'-DDD for cushing's syndrome: evidence for the sites of action of the drug
- 4) An Effect of o,p’-DDD on the Extra-adrenal Metabolism of Cortisol in Man
- 5) Update in adrenocortical carcinoma (a review)
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。